AU2019271285B2 - Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors - Google Patents

Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors Download PDF

Info

Publication number
AU2019271285B2
AU2019271285B2 AU2019271285A AU2019271285A AU2019271285B2 AU 2019271285 B2 AU2019271285 B2 AU 2019271285B2 AU 2019271285 A AU2019271285 A AU 2019271285A AU 2019271285 A AU2019271285 A AU 2019271285A AU 2019271285 B2 AU2019271285 B2 AU 2019271285B2
Authority
AU
Australia
Prior art keywords
ing
lung
fibroblasts
formula
mammalian subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019271285A
Other languages
English (en)
Other versions
AU2019271285A1 (en
Inventor
Steven Idell
Torry A. TUCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actuate Therapeutics Inc
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of AU2019271285A1 publication Critical patent/AU2019271285A1/en
Application granted granted Critical
Publication of AU2019271285B2 publication Critical patent/AU2019271285B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019271285A 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors Active AU2019271285B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672864P 2018-05-17 2018-05-17
US62/672,864 2018-05-17
PCT/US2019/032639 WO2019222483A1 (en) 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Publications (2)

Publication Number Publication Date
AU2019271285A1 AU2019271285A1 (en) 2020-12-03
AU2019271285B2 true AU2019271285B2 (en) 2024-10-03

Family

ID=68541026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019271285A Active AU2019271285B2 (en) 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Country Status (11)

Country Link
US (1) US12083098B2 (https=)
EP (1) EP3793545A4 (https=)
JP (2) JP7471660B2 (https=)
KR (1) KR20210038429A (https=)
CN (1) CN112437663A (https=)
AU (1) AU2019271285B2 (https=)
BR (1) BR112020023422A2 (https=)
CA (1) CA3100381A1 (https=)
IL (1) IL278761B2 (https=)
MX (1) MX2020012331A (https=)
WO (1) WO2019222483A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020415440A1 (en) * 2019-12-26 2022-08-04 Actuate Therapeutics, Inc. Compounds for the treatment of myelofibrosis
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib
CN117981712B (zh) * 2023-07-24 2025-02-28 南京鼓楼医院 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622987C (en) 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
KR101862291B1 (ko) * 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
WO2014165851A1 (en) 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
EP3665176B1 (en) * 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu

Also Published As

Publication number Publication date
CN112437663A (zh) 2021-03-02
JP7471660B2 (ja) 2024-04-22
US12083098B2 (en) 2024-09-10
JP2024069221A (ja) 2024-05-21
US20210212988A1 (en) 2021-07-15
EP3793545A4 (en) 2022-04-06
KR20210038429A (ko) 2021-04-07
IL278761A (en) 2021-01-31
WO2019222483A1 (en) 2019-11-21
MX2020012331A (es) 2021-03-09
CA3100381A1 (en) 2019-11-21
EP3793545A1 (en) 2021-03-24
AU2019271285A1 (en) 2020-12-03
IL278761B1 (en) 2024-11-01
BR112020023422A2 (pt) 2021-02-17
IL278761B2 (en) 2025-03-01
JP2021523951A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
JP2024069221A (ja) グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
US20190255042A1 (en) Application of hedgehog pathway inhibitor in treating fibrosis diseases
CN114026072A (zh) 治疗特发性肺纤维化的方法
CN105061346A (zh) 溶血磷脂酸受体的多环拮抗剂
JP2016520130A (ja) 心臓疾患における新規治療戦略としてのｂｅｔ阻害
US11529324B2 (en) Use of Kv11.1 channel inhibitors for treatment of pulmonary hypertension
AU2019338236B2 (en) A GABAA receptor ligand
JP2024517396A (ja) ペプチドアミド系化合物の、掻痒を治療するための薬物の製造における用途
US20250312332A1 (en) Treatment of muscle fibrosis
KR20100116177A (ko) 근골격-관련 장애의 치료에서 헤지호그 효능제의 용도
IL295452A (en) Use of cyclosporine analogues for treating fibrosis
JP7762224B2 (ja) 線維化症の予防または治療用薬学的組成物
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40057209B (en) A gabaa receptor ligand
HK40057209A (en) A gabaa receptor ligand

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)